COMPANY

CinDome Pharma

HQ: Cincinnati, OH source · cindome.com ↗

Keywords: gastroparesis Diabetic Gastroparesis Idiopathic Gastroparesis CIN-102

Location: Cincinnati, OH · source · Oct 15, 2026

Profile checked Oct 10, 2026

Raises and deals from press releases

Raise Series B extension · $40M · announced May 16, 2024 Company release ↗
Source quote
- May 16, 2024 · Company release ↗
  “CINCINNATI – May 16, 2024 – CinDome Pharma, a CinRx portfolio company dedicated to advancing a safe, chronic therapy for gastroparesis, today announced a $40 million Series B financing extension”

Raises announced in these releases: $40M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Jan 29, 2025 Trial start Phase 2: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis. source ↗
May 16, 2024 Raise Series B extension · $40M source ↗
Mar 27, 2023 Trial start Phase 2: A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis source ↗
Feb 17, 2020 Trial start Phase 2: A Scintigraphy Study in Adults With Diabetic Gastroparesis source ↗
Sep 11, 2019 Trial start 2: A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT06899217	A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.	Phase 2	Completed	Jan 29, 2025	May 7, 2026 (actual)
NCT04026997	A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis	2	Terminated	Sep 11, 2019	Dec 17, 2020 (actual)
NCT05832151	A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis	Phase 2	Completed	Mar 27, 2023	Nov 14, 2025 (actual)
NCT04208698	A Scintigraphy Study in Adults With Diabetic Gastroparesis	Phase 2	Terminated	Feb 17, 2020	Mar 31, 2020 (actual)